Actavis Recalls Dextroamphetamine Tablets Due to Impurity Failures
Actavis Elizabeth LLC is recalling 182,378 bottles of 30 mg Dextroamphetamine and Amphetamine tablets because they failed impurity specifications.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which typically involves a situation where use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences. The source text does not report any illnesses, injuries, or fatalities, and the hazard is a failure of impurity specifications rather than a known high-risk pathogen or structural defect.
Plain-English summary
Actavis Elizabeth LLC is recalling 182,378 bottles of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Tablets, 30 mg, 100 ct. The recall is being conducted because the product failed impurities/degradation specifications, specifically being out of specification for impurities.
The affected product is prescription-only and was distributed nationwide in the United States. The recall covers 14 specific lot numbers with expiry dates ranging from February 2016 to May 2017. The product was manufactured by Actavis Elizabeth LLC and distributed by Actavis, Inc.
Consumers and healthcare providers should check their inventory for the specific lot numbers and expiry dates listed in the recall notice. If the product is found, it should be returned to the pharmacy or distributor for credit or replacement. Patients should consult their healthcare provider for alternative treatment options if necessary.
The recalled product
- Product
- Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Tablets, 30 mg, 100 ct. bottle, Rx Only. Manufactured by: Actavis Elizabeth LLC, Elmora Avenue, Elizabeth, NJ 07207. Distributed by: Actavis, Inc., 80 Columbia Road, Bldg B, M
- Manufacturer
- Actavis Elizabeth LLC
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 182,378
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot #: 1879E141
- Expiry 02/16
- Lot #: 1880E141
- Expiry: 02/16
- Lot #: 5034M142
- Expiry: 5/16
- Lot #: 0422A151
- Expiry: 7/16
- Lot #: 0423A151
- Lot #: 1053C151
- Expiry: 8/16
- Lot #: 1054C151
- Lot #: 2197E152
- Expiry: 11/16
- Lot #: 2198E151
- Expiry: 12/16
- Lot #: 2662F151
- Lot #: 2672F152
- Expiry: 3/17
- Lot #: 3121G152
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 4 recalled by Actavis Elizabeth LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 4 products in this recall →Related recalls
Same manufacturer · Actavis Elizabeth LLC
See all →- ModerateActavis Recalls Nifedipine Capsules Due to Presence of Foreign Tablets
FDA (Drugs) · 2016-11-30
- ModerateActavis Recalls Dextroamphetamine Tablets for Impurity Failures
FDA (Drugs) · 2016-04-13
- SevereActavis Recalls Dextroamphetamine Tablets Due to Impurity Failures
FDA (Drugs) · 2016-04-13
- SevereActavis Recalls Amphetamine Tablets Due to Impurity Failures
FDA (Drugs) · 2016-04-13
- ModerateActavis Recalls Dextroamphetamine Sulfate Capsules for Dissolution Failures
FDA (Drugs) · 2015-03-11
Same hazard · impurity failure
See all →- LowDabigatran Etexilate Capsules Recalled Due to Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- ModerateDigoxin Tablets Recalled Due to Failed Impurity and Degradation Specifications
FDA (Drugs) · 2024-04-24
- HighPrescription Rifampin Capsules Recalled Due to Failed Quality Specifications
FDA (Drugs) · 2023-01-25
- SevereOxycodone Hydrochloride Oral Solution Recall Due to Impurity Failure
FDA (Drugs) · 2022-03-16
- LowBausch Health Recalls Mephyton Tablets Due to Impurity D Failure
FDA (Drugs) · 2021-02-03